Net loss of Concord Drugs reported to Rs 0.24 crore in the quarter ended December 2023 as against net profit of Rs 0.45 crore during the previous quarter ended December 2022. Sales declined 5.54% to Rs 12.78 crore in the quarter ended December 2023 as against Rs 13.53 crore during the previous quarter ended December 2022. ParticularsQuarter Ended�Dec. 2023Dec. 2022% Var. Sales12.7813.53 -6 OPM %4.9310.64 - PBDT0.131.00 -87 PBT-0.260.62 PL NP-0.240.45 PL Powered by Capital Market - Live News

Concord Drugs will hold a meeting of the Board of Directors of the Company on 13 February 2024.Powered by Capital Market - Live News

Net profit of Concord Drugs rose 211.11% to Rs 0.56 crore in the quarter ended September 2023 as against Rs 0.18 crore during the previous quarter ended September 2022. Sales declined 45.19% to Rs 7.52 crore in the quarter ended September 2023 as against Rs 13.72 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales7.5213.72 -45 OPM %21.418.67 - PBDT1.190.77 55 PBT0.800.24 233 NP0.560.18 211 Powered by Capital Market - Live News

Net profit of Concord Drugs rose 194.44% to Rs 0.53 crore in the quarter ended September 2023 as against Rs 0.18 crore during the previous quarter ended September 2022. Sales declined 46.21% to Rs 7.38 crore in the quarter ended September 2023 as against Rs 13.72 crore during the previous quarter ended September 2022. ParticularsQuarter Ended�Sep. 2023Sep. 2022% Var. Sales7.3813.72 -46 OPM %20.738.67 - PBDT1.150.77 49 PBT0.770.24 221 NP0.530.18 194 Powered by Capital Market - Live News

Concord Drugs announced that the 28th Annual General Meeting (AGM) of the company will be held on 30 September 2023.Powered by Capital Market - Live News